The alfapump® system is currently not approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Sequana Medical is a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders
Ian Crosbie

Chief Executive Officer

“We have demonstrated that the alfapump® addresses the clear unmet patient needs in liver refractory ascites and malignant ascites, delivering a clinically effective and convenient therapy that improves patient quality of life.

Through our breakthrough and proprietary Direct Sodium Removal therapy, we are developing alfapump® DSR, a convenient and fully implanted system for the management of volume overload due to heart failure.

This IPO will provide the financing for the North American pivotal study on the alfapump® for liver refractory and recurrent ascites, the European commercial roll-out of the alfapump®, first-in-human DSR studies, other clinical programmes in Europe including a study on the alfapump® for malignant ascites, a registry for cirrhosis patients that have been implanted with the alfapump® and a study on the impact of albumin replacement therapy on clinical outcomes in alfapump® patients, the partial repayment of principal on an outstanding loan and other general corporate purposes.”